Latozinemab
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neurodegenerative Diseases
Conditions
Neurodegenerative Diseases
Trial Timeline
Dec 8, 2023 → Jan 7, 2026
NCT ID
NCT06111014About Latozinemab
Latozinemab is a phase 3 stage product being developed by Alector for Neurodegenerative Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT06111014. Target conditions include Neurodegenerative Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06111014 | Phase 3 | Terminated |
Competing Products
5 competing products in Neurodegenerative Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONO-2808 + Placebo | Ono Pharmaceutical | Phase 1 | 33 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |
| Pimavanserin | Acadia Pharmaceuticals | Approved | 80 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 72 |
| Blood sampling, skin biopsy, excreta sampling, lumbar puncture | Brain Biotech | Pre-clinical | 15 |